# Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

> **NCT03197012** · EARLY_PHASE1 · COMPLETED · sponsor: **Thomas Hope** · enrollment: 10 (actual)

## Conditions studied

- Neuroendocrine Tumor

## Interventions

- **DRUG:** 90Y-DOTA-TOC
- **DRUG:** 68Ga-DOTA-TOC

## Key facts

- **NCT ID:** NCT03197012
- **Lead sponsor:** Thomas Hope
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2019-05-31
- **Final completion:** 2019-05-31
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03197012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03197012, "Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03197012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*